Have a specific question about your LBP project? Click below and let’s get started.
Sun, Z;Zhao, H;Fang, D;Davis, CT;Shi, DS;Lei, K;Rich, BE;Winter, JM;Guo, L;Sorensen, LK;Pryor, RJ;Zhu, N;Lu, S;Dickey, LL;Doty, DJ;Tong, Z;Thomas, KR;Mueller, AL;Grossmann, AH;Zhang, B;Lane, TE;Fujinami, RS;Odelberg, SJ;Zhu, W;
Breakdown of the blood-central nervous system barrier (BCNSB) is a hallmark of many neuroinflammatory disorders, such as multiple sclerosis (MS). Using a mouse model of MS, experimental autoimmune encephalomyelitis (EAE), we show that endothelial-to-mesenchymal transition (EndoMT) occurs in the CNS before the onset of clinical symptoms and plays a major role in the breakdown of BCNSB function. EndoMT can be induced by an IL-1β-stimulated signaling pathway in which activation of the small GTPase ADP ribosylation factor 6 (ARF6) leads to crosstalk with the activin receptor-like kinase (ALK)-SMAD1/5 pathway. Inhibiting the activation of ARF6 both prevents and reverses EndoMT, stabilizes BCNSB function, reduces demyelination, and attenuates symptoms even after the establishment of severe EAE, without immunocompromising the host. Pan-inhibition of ALKs also reduces disease severity in the EAE model. Therefore, multiple components of the IL-1β-ARF6-ALK-SMAD1/5 pathway could be targeted for the treatment of a variety of neuroinflammatory disorders.